Navigation Links
Clinical trials for first-ever human hookworm vaccine advance
Date:11/5/2012

WASHINGTON, D.C.November 5, 2012The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm vaccine. Part II of the trial commenced in Americaninhas, Brazil, following successful vaccinations in Part I of the study, which began in Belo Horizonte, Brazil in late 2011.

An independent Safety Monitoring Committee (SMC) recently reviewed results from Part I of the study and determined that no safety issues had been observed after vaccinating healthy adults who had never been exposed to hookworm. They concluded that these promising results were sufficient to allow researchers to proceed to the next stage of the trial, in which hookworm-exposed adults will receive the vaccine candidate.

Part II of the study is taking place in Americaninhas, a hookworm-endemic region of Brazil. The trial will enroll 66 healthy, hookworm-exposed adults between the ages of 18 and 45. Each volunteer will receive three injections over four months. Researchers will then follow each volunteer for 12 additional months, monitoring the vaccine's safety and analyzing the recipients' immune responses.

"Eventually, a human hookworm vaccine will be used to protect children at risk of infection. Because the hookworm-exposed population being vaccinated in Part II of this trial is representative of the eventual target population, we're closer to making this goal a reality," said Dr. David Diemert, the trial's principal investigator.

The trial is being conducted in partnership with a team based at the Oswaldo Cruz Foundation (FIOCRUZ) of the Brazilian Ministry of Health, a member of the Sabin Vaccine Institute Product Development Partnership (Sabin PDP).

"Moving forward with this trial helps advance the Sabin PDP's larger goal to develop safe, efficacious and low-cost vaccines for diseases of poverty," said Dr. Peter Hotez, president of the Sabin Vaccine Institute. "A human hookworm vaccine will help more than 600 million people worldwide who currently suffer from the infection."

Hookworm is a soil-transmitted helminth infection caused by the intestinal parasites Necator americanus and Ancylostoma duodenale. Although people living in most middle- and upper-income countries are largely free from the suffering caused by hookworm, the infection remains widespread in tropical and sub-tropical climates of Africa, Asia and Latin America. Left untreated, hookworm infection causes intestinal blood loss leading to iron-deficiency anemia and protein malnutrition, which in turn can result in impaired physical and cognitive development in children.
'/>"/>

Contact: Johanna Harvey
johanna.harvey@sabin.org
202-621-1691
Sabin Vaccine Institute
Source:Eurekalert

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
Breaking Medicine Technology: